The Ependymoma Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies
New York, NY -- (SBWIRE) -- 07/18/2017 -- Ependymoma are tissue-based tumors arising from the cells lining the ventricles and central canal within the spinal cord. Symptoms of ependymal tumors are related to the area within the brain and size of the tumor. Increased head size may be one of the first symptoms noted in pediatric patients. Irritability, sleeplessness, and vomiting symptoms may develop with growth of tumor. In older children and adults, nausea, vomiting, and headache, are the most common symptoms noted. According to American Brain Tumor Association, ependymomas are relatively rare tumors occurring in adults, accounting for 2-3% of primary brain tumors. However, there are the sixth most common brain tumor occurring in pediatric patients. About 30% of pediatric ependymoma are diagnosed in children younger than three years of age. Like many tumor types, the exact cause of ependymoma is not known. Unknown causes and lucrative revenue prospects have grabbed attention from big drug makers and thus the market is expected to exhibit significant growth in market value over the forecast years.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/10723
Based on disease type, myxopapillary ependymomas occur primarily at the base area of spine called filum terminale. This disease is uncommon in children. Subependymomas are usually incidental tumors and are most uncommon in children. Classic ependymomas can arise anywhere in the central nervous system, but commonly develop in the posterior fossa. Anaplastic ependymomas, in general, exhibit high growth rate and currently exhibit inadequate prognosis. Most common treatments of ependymoma include surgical removal of ependymoma or by radiotherapy. Though specific medicinal therapies are not available for treating ependymoma, certain drugs can be used to treat the symptoms of disease. Chemotherapy could be used to ascertain the continuation of the metastases process. Physicians could also prescribe anticonvulsants and steroids to reduce symptoms of ependymoma.
Geographically, North America dominates global ependymoma market followed by Europe due to availability of highly developed healthcare infrastructure and sophisticated treatment technologies. Asia-Pacific is expected to emerge as promising market for ependymoma due to increasing medical tourism industry, increase in purchasing power, rapidly improving healthcare infrastructure and increased awareness on overall healthcare and available treatments.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/10723
Key companies operational in global ependymoma market are Eli Lilly and Company, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics,Inc., Cellectar Biosciences, Inc., and others.
About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.
PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.